- FDA approves Bristol-Myers Squibb's, AstraZeneca's Farxiga
- FDA advisory committee recommends approval for Bristol-Myers Squibb's, AstraZeneca's metreleptin in generalized lipodystrophy
- Bristol-Myers Squibb sells off diabetes business
- CVS Caremark study: More education needed on genetic testing in prescribing antiplatelet drugs
- FDA approves Mekinist in combination with Tafinlar to treat patients with advanced melanoma
NEW YORK — Bristol-Myers Squibb has completed its acquisition of a developer of hepatitis C treatments.
Bristol said it successfully completed its tender offer for all of the outstanding shares of common stock of Alpharetta, Ga.-based Inhibitex, at a purchase price of $26 per share via a “short form merger” in which all such shares were converted into the right to receive the aforementioned share price in cash and without interest, less any applicable withholding taxes.
Bristol said it intends to delist and de-register Inhibitex common stock as promptly as practicable following the effective time of the merger.